Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;59(4):493-503.
doi: 10.1016/j.amepre.2020.06.011. Epub 2020 Jul 15.

Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention

Sarah M Bartsch  1 , Kelly J O'Shea  1 , Marie C Ferguson  1 , Maria Elena Bottazzi  2 , Patrick T Wedlock  1 , Ulrich Strych  2 , James A McKinnell  3 , Sheryl S Siegmund  1 , Sarah N Cox  1 , Peter J Hotez  2 , Bruce Y Lee  4
Affiliations

Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention

Sarah M Bartsch et al. Am J Prev Med. 2020 Oct.

Abstract

Introduction: Given the continuing COVID-19 pandemic and much of the U.S. implementing social distancing owing to the lack of alternatives, there has been a push to develop a vaccine to eliminate the need for social distancing.

Methods: In 2020, the team developed a computational model of the U.S. simulating the spread of COVID-19 coronavirus and vaccination.

Results: Simulation experiments revealed that to prevent an epidemic (reduce the peak by >99%), the vaccine efficacy has to be at least 60% when vaccination coverage is 100% (reproduction number=2.5-3.5). This vaccine efficacy threshold rises to 70% when coverage drops to 75% and up to 80% when coverage drops to 60% when reproduction number is 2.5, rising to 80% when coverage drops to 75% when the reproduction number is 3.5. To extinguish an ongoing epidemic, the vaccine efficacy has to be at least 60% when coverage is 100% and at least 80% when coverage drops to 75% to reduce the peak by 85%-86%, 61%-62%, and 32% when vaccination occurs after 5%, 15%, and 30% of the population, respectively, have already been exposed to COVID-19 coronavirus. A vaccine with an efficacy between 60% and 80% could still obviate the need for other measures under certain circumstances such as much higher, and in some cases, potentially unachievable, vaccination coverages.

Conclusions: This study found that the vaccine has to have an efficacy of at least 70% to prevent an epidemic and of at least 80% to largely extinguish an epidemic without any other measures (e.g., social distancing).

PubMed Disclaimer

Figures

Figure 1
Figure 1
Percentage reduction in SARS-CoV-2 cases at the epidemic peak for a vaccine that prevents infection compared with no vaccination, varying with vaccine efficacy, vaccination coverage, R0, and vaccination onset (percentage of population exposed to SARS-CoV-2) occurring when (A) 0% of the population has been exposed, (B) 5% of the population has been exposed, (C) 15% of the population has been exposed, and (D) 30% of population has been exposed.
Figure 2
Figure 2
The total number of SARS-CoV-2 cases averted by vaccination during the course of the epidemic for a vaccine that prevents infection compared with no vaccination, varying with vaccine efficacy, vaccination coverage, R0, and vaccination onset (percentage of population exposed to SARS-CoV-2) occurring when A) 0% of the population has been exposed, B) 5% of the population has been exposed, C) 15% of the population has been exposed, and D) 30% of the population has been exposed.
Figure 3
Figure 3
Percentage reduction in SARS-CoV-2 cases at the epidemic peak and the total number of SARS-CoV-2 cases averted by vaccination during the course of the epidemic compared with no vaccination for (A) a vaccine that reduces viral shedding when vaccination onset occurs when 0% of the population has been exposed to SARS-CoV-2, (B) for a vaccine that prevents infection when asymptomatic cases are as infectious as symptomatic cases when vaccination onset occurs when 0% of the population has been exposed, and (C) for a vaccine that prevents infection when asymptomatic cases are as infectious as symptomatic cases when vaccination onset occurs when 15% of the population has been exposed. R0, reproduction number.
See this image and copyright information in PMC

Update of

References

    1. Lee BY, Burke DS. Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles. Vaccine. 2010;28(16):2806–2809. doi: 10.1016/j.vaccine.2009.09.047. - DOI - PMC - PubMed
    1. Lee BY, Mueller LE, Tilchin CG. A systems approach to vaccine decision making. Vaccine. 2017;35(suppl 1):A36–A42. doi: 10.1016/j.vaccine.2016.11.033. - DOI - PMC - PubMed
    1. COVID-19 treatment and vaccine tracker. Milken Institute, FasterCures. https://covid-19tracker.milkeninstitute.org. Accessed May 11, 2020.
    1. Mapping COVID-19 research: the “map of hope” provides a geographical overview of planned, ongoing and completed clinical trials. Heidelberg Institute for Geoinformation Technology.https://covid-19.heigit.org/clinical_trials.html. Updated May 11, 2020. Accessed May 11, 2020.
    1. Thanh Le T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(5):305–306. doi: 10.1038/d41573-020-00073-5. - DOI - PubMed

Publication types

MeSH terms